21 May 2009
Low response to antiviral therapy for recurrent liver graft infection with hepatitis C virus genotype 1B
J Ziółkowski, L Pączek, G Senatorski, D Porowski, K Zieniewicz, B Ziarkiewicz- Wróblewska, M KrawczykAnn Transplant 2009; 14(1): 28-28 :: ID: 880300
Abstract
Background: Hepatitis C recurrence is a common complication after liver
transplantation and leads to liver failure and early graft loss. The aim of our study was to evaluate effectiveness of treatment with pegylated interferon with ribavirin on virus C eradication. 30 patients with HCV recurrence were followed during the antiviral therapy and 12 months after the end of the treatment. There were 25 patients with HCV genotype 1b, one patient with genotype 3a. 4 patients' genotyping were not done. Before therapy, mean Fibrosis Score was 0.8, and mean Hepatitis Activity Index 6.5. 41% of patients discontinued therapy or have lowered the dose of medications, because of adverse events. By the end of the treatment, HCV negative were 10 patients (34%), after next 12 months HCV negative were only 3 of them (10%) (2 patients with genotype 1b, 1 patient with genotype 3a). Serum virus load was lower at the end of antiviral treatment compared to the pre-therapy load in 11 (60%) patients with persistent viraemia; however at the end of the follow-up virus load was lower only in 8 patients (30%). Liver biopsy (n=9) showed progression of fibrosis or hepatitis in patients which did not eradicate C virus, despite lowering the virus load during the antiviral treatment. In all 4 cases of re-therapy the HCV was not eradicated.
Conclusions: Antiviral treatment of HCV genotype 1b recurrence after liver
transplantation with pegylated interferon and ribavirin gives small percent
of eradication. There is no improvement in histological changes after antiviral treatment in a group of patients without eradication.
Keywords: Liver Transplantation
In Press
18 Mar 2024 : Original article
Does Antibiotic Use Increase the Risk of Post-Transplantation Diabetes Mellitus? A Retrospective Study of R...Ann Transplant In Press; DOI: 10.12659/AOT.943282
20 Mar 2024 : Original article
Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single InstitutionAnn Transplant In Press; DOI: 10.12659/AOT.942252
28 Mar 2024 : Original article
Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical T...Ann Transplant In Press; DOI: 10.12659/AOT.942823
02 Apr 2024 : Original article
Liver Transplantation from Brain-Dead Donors with Hepatitis B or C in South Korea: A 2014-2020 Korean Organ...Ann Transplant In Press; DOI: 10.12659/AOT.943588
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860